Advanced searches left 3/3

Heart Failure - Europe PMC

Summarized by Plex Scholar
Last Updated: 19 June 2022

* If you want to update the article please login/register

Respiratory failure and bioelectrical phase angle are independent predictors for long-term survival in acute heart failure.

" The evaluation of long-lasting mortality in intense decompensated heart failure is challenging. Respiratory failure and blockage play an essential role in risk stratification of ADHF patients. The goal of this research was to explore the effect of arterial blood gases and blockage on long-lasting mortality in patients with ADHF. We signed up 252 patients with ADHF. Respiratory failure types I and II were observed in 78 and 53 patients, respectively. The ROC analyses disclosed that the cut-off points for anticipating death were: BNP > 441 pg/mL, BUN > 1. 67 mmol/L, partial pressure in oxygen \ u226469. 7 mmHg, and stage angle \ u22644. 9 \ u00b0. Taken together, these 4 variables proved to be excellent predictors for long-term mortality in ADHF, hence describing 60% of all deaths. A multiparametric method based on measurements of BNP, BUN, PaO 2, and stage angle is a dependable strategy for long-lasting forecast of mortality risk in patients with ADHF. ".

Source link: https://europepmc.org/article/MED/35389300


Paeonol attenuates heart failure induced by transverse aortic constriction via ERK1/2 signalling.

" Context Paeonol is the main phytochemical from Cortex Moutan. Objective The research investigates the results and underlying mechanisms of PAE on transverse aortic restriction -generated heart failure in mice. Materials and approaches C57BL/6 mice were randomly separated into 5 groups: sham, TAC, PAE, pae10 and pae20 50. Serum degrees of atrial natriuretic peptide, tumor death element- \ u03b1 and interleukin-6 were measured by enzyme-linked immunosorbent assay. Myocardial apoptosis was discovered with incurable deoxynucleotidyl transferase-mediated dUTP nick end-labelling staining. Outcomes Echocardiography showed PAE enhanced heart function and H&E discoloration showed PAE eased myocardial injury. Western and qRT-PCR results revealed that PAE down-regulated the levels of BNP, \ and anp u03b1-MHC. Masson and western results revealed PAE hindered heart hypertrophy. Conversation and verdicts Paeonol regulates ERK1/2/JNK to improve heart function, which provides theoretical support for the comprehensive clinical treatment of HF. ".

Source link: https://europepmc.org/article/MED/35249458


Injection of YiQiFuMai powder protects against heart failure via inhibiting p38 and ERK1/2 MAPKs activation.

" Materials and techniques Kinase restraint profiling assays with 2 mg/mL YQFM were carried out against a collection of 408 kinases. In vivo, HF with minimized ejection fraction was induced by long-term left former descending coronary artery ligation for 6 weeks in male Sprague-Dawley rats. Then, HFrEF mice were treated with 0. 46 g/kg YQFM or sugar pill daily for 2 weeks. Outcomes Kinase inhibition profiling analysis demonstrated that mitogen-activated protein kinases moderated the signalling cascades of YQFM during HF therapy. In rats, the control group had lower left ventricular ejection fraction at 37 \ u00b1 1. 7% compared to the YQFM group at 54 \ u00b1 1. 1%. Cardiac fibrosis degrees in control group rats were significantly higher than YQFM group. Final thoughts Our collective in vitro and in vivo experiments showed that YQFM boosts left ventricular function and prevents fibrosis in HFrEF rats by preventing MAPK signalling pathways. ".

Source link: https://europepmc.org/article/MED/35244521


The Diagnosis and Treatment of Postoperative Right Heart Failure.

" Background Acute right heart failure is a dangerous condition that can arise postoperatively. Methods This evaluation is based on publications retrieved by a selective literature search in PubMed as well as on standards from Germany and abroad. Results The analysis of right heart failure is chiefly based on echocardiography and lung arterial catheterization and is planned to lead to prompt therapy. Along with therapy of the source of the condition, supportive management is vital to patient survival. The in-hospital mortality of postoperative right heart failure is 5-17 %. The outcomes of the use of heart support group reported in situation collection are unsatisfactory, yet however good compared to what these seriously unwell patients would deal with without such therapy. Refresher courses on the use of mechanical and medicinal heart support systems must be performed to provide more powerful evidence on which therapy referrals can be based. ".

Source link: https://europepmc.org/article/MED/35583115


Catheter-Based Management of Heart Failure: Pathophysiology and Contemporary Data.

" Device therapy for severe heart failure has shown effectiveness both in persistent and acute settings. Recent percutaneous device advancements have originated an area referred to as interventional HF, supplying medical professionals with a selection of alternatives for severe decompensated HF that are fixated nonsurgical mechanical circulatory support. Remote hemodynamic surveillance tools have also been revealed to be efficacious for the ambulatory management of HF. ".

Source link: https://europepmc.org/article/MED/35710282


Leading Multisector Partnerships to Address Social Determinants of Health and Advance Health Equity for an Underresourced Heart Failure Patient Population.

" Addressing the social components of wellness to breakthrough health equity for individuals with heart failure is an intricate undertaking. We explain the evolution of an academic-practice-community partnership addressing the SDoH to advancement health and wellness equity for a population of underresourced heart failure patients. Our multisector collaborations to resolve SDoH and advance health equity provide a structure to improve population health and wellness results for underresourced persons with heart failure. ".

Source link: https://europepmc.org/article/MED/35639528


Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H 2 Receptor Blockers.

" Purpose Acid suppressive therapy utilizing histamine H 2 receptor antagonists and proton pump inhibitors can be used for the prevention of gastrointestinal bleeding amongst patients with heart disease getting double antiplatelet therapy. Current searchings for PPIs were initially championed as better than H2RAs for preventing GIB events in cardiovascular disease patients on DAPT therapy, yet there is proof to recommend that drug-drug communications between clopidogrel and PPIs may translate to even worse cardio end results. As a result, there is restored passion in H2RAs for patients on DAPT with some data showing comparable or improved scientific end results over PPI therapy. Studies comparing H2RAs and PPIs in patients on DAPT have demonstrated mixed outcomes for cardiovascular and GIB results, with several studies being underpowered and limited by predispositions. These findings recommend that H2RAs may require reconsideration as an acid suppressive therapy over PPIs for patients on DAPT or with HF. ".

Source link: https://europepmc.org/article/MED/35715526


New-Onset Heart Failure in the Setting of T4-Conversion Disorder

" Thyroid hormone is essential in completing the appropriate metabolic rate of the body. We present a case of an 80-year-old female with a history of hypertension, coronary artery disease, chronic kidney disease, hypothyroidism because of total thyroidectomy, and an analytical vascular accident that provided with slurred speech, decreased appetite, dizziness and lethargy with new-onset weakness. Brain MRI exposed no acute pathology. She was provided her home dosage of Levothyroxine and was confessed to the telemetry device for evaluation of her symptoms and abnormal thyroid panel. An echocardiogram revealed a new badly minimized left ventricular function with extreme global hypokinesis of the left ventricle and an ejection fraction of 30%. It was only after initiating combination therapy of levothyroxine and liothyronine that her symptoms and abnormal cardiac rhythm settled. With this careful titration of the patient \ u2019s medication, we ended that combination therapy was vital to the patient being euthyroid. ".

Source link: https://europepmc.org/article/MED/PMC9197626


Impact of patient engagement in a French telemonitoring programme for heart failure on hospitalization and mortality.

" Aims Management of patients with lately decompensated heart failure by healthcare facility services is expensive, complex to strategy, and not always reliable. Telemedicine programmes in heart failure might improve the quality of treatment, but their efficiency is inadequately documented in real-world settings. The study intends to assess the influence of patient interaction in home-based telemonitoring for heart failure on rehospitalization and death rates. SCAD is a patient-oriented service of home-based interactive telemonitoring offered to heart failure patients during a hospital stay that accept take part in a healing education and learning program. Information were linked on a patient-by-patient basis in between the SCAD data source and the French national health insurance policy database. Rehospitalization rates for heart disease decreased from 79. 4% in the year coming before enrolment to 41. 1% in the following year and from 52. 8% to 18. 8% for hospital stays for heart failure. The 12 month mortality rate was 11. 2%. Significant associations were observed in between degree of use of the SCAD program and all-cause rehospitalization, rehospitalization for cardio disease, rehospitalization for heart failure, and death in the 12 months following enrolment. The mean number of days to life outside health center were 279 \ u00b1 111 in low users, 312 \ u00b1 90 in intermediate users, and 304 \ u00b1 100 in high users. Conclusions Educational home telemonitoring of patients with heart failure complying with hospitalization provides lasting medical benefits in terms of rehospitalization and death in real-world setups, according to the degree of use of the programme by the patient. ".

Source link: https://europepmc.org/article/MED/35715956


Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.

" Background Trial Evaluating Cardiovascular Outcomes with Sitagliptin analyzed the cardiovascular safety and security of sitagliptin versus placebo on curriculum vitae end results in patients with type 2 diabetes and curriculum vitae disease and found sitagliptin noninferior to placebo. Techniques TIMI settled in a blinded style all prospective a hospital stay for heart failure events, all potential MACE+ occasions formerly adjudicated as not an endpoint event, and a random subset of MACE+ occasions previously adjudicated as an endpoint event. Results After re-adjudication of possible HHF occasions in the intent-to-treat population, there were 224 patients with a validated event in the sitagliptin arm and 239 patients in the placebo arm, representing a threat proportion of 0. 94. Conclusion The results of this independent re-adjudication procedure and analyses of CV outcomes from TECOS were consistent with the initial adjudication results and overall research study findings. ".

Source link: https://europepmc.org/article/MED/35715946

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions